Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
This selectivity profile
3800 and 6000 nM for MET
Cefoselis hydrochloride exhibits good activity against a wide range of Gram-positive and Gram-negative organisms
which induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines
20% SBE-β-CD in saline: Guidelines (Following is our recommended protocol
SU14813 maleate - CAS# 849643-15-8 Size:Solid 10 mg This selectivity profileSU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet derived growth factor receptors (PDGFR), KIT, and fms like tyrosine kinase 3 (FLT 3) (1). SU14813 was developed as a next generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity
US$ 185.50
US$ 18.99
US$ 20.00
US$ 165.50
US$ 171.50
US$ 617.98